Ampicillin + Sulbactam (Powder) Instructions for Use
ATC Code
J01CR01 (Ampicillin and beta-lactamase inhibitor)
Active Substances
Ampicillin (Rec.INN registered by WHO)
Sulbactam (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Broad-spectrum penicillin antibiotic with a beta-lactamase inhibitor
Pharmacotherapeutic Group
Systemic antibacterial agents; beta-lactam antibacterial agents, penicillins; combinations of penicillins, including combinations with beta-lactamase inhibitors
Pharmacological Action
A combined broad-spectrum antibacterial agent.
Ampicillin is an antibiotic from the group of semi-synthetic penicillins, whose bactericidal action is associated with the inhibition of microorganism cell wall protein synthesis.
Sulbactam is an irreversible beta-lactamase inhibitor; it expands the spectrum of ampicillin activity against resistant strains whose resistance develops under the influence of beta-lactamases; it does not alter the activity of ampicillin against susceptible strains; by binding to some penicillin-binding proteins of bacteria, it exhibits synergism when used simultaneously with beta-lactam antibiotics. It is stable in aqueous solution, has independent antibacterial activity against the Neisseriaceae family and Acinetobacter spp., and is resistant to the action of most plasmid beta-lactamases.
The combination of Ampicillin+Sulbactam exhibits activity against aerobic gram-positive bacteria – Staphylococcus aureus (beta-lactamase-producing and non-producing strains), Staphylococcus epidermidis (beta-lactamase-producing and non-producing strains), Staphylococcus saprophyticus (beta-lactamase-producing and non-producing strains), Streptococcus pyogenes, Streptococcus pneumoniae (including penicillin-resistant strains), Streptococcus spp. of the viridans group, Enterococcus faecalis, Listeria monocytogenes; aerobic gram-negative bacteria – Escherichia coli, Proteus mirabilis, Proteus vulgaris, Klebsiella spp., Neisseria gonorrhoeae (beta-lactamase-producing and non-producing strains), Moraxella catarrhalis (beta-lactamase-producing and non-producing strains), Morganella morganii, Haemophilus influenzae (including ampicillin-resistant strains), Providencia rettgeri, Providencia stuartii; anaerobic microorganisms – Bacteroides spp., including Bacteroides fragilis, Clostridium spp. (except Clostridium difficile), Peptococcus spp., Peptostreptococcus spp.
Resistant: methicillin-resistant Staphylococcus spp., Citrobacter spp., most strains of Enterobacter spp., Pseudomonas aeruginosa, Mycobacterium spp., Clostridium difficile, Chlamydia pneumoniae, Mycoplasma pneumoniae.
Pharmacokinetics
It penetrates into most tissues and body fluids; during inflammation, permeability into the cerebrospinal fluid increases sharply.
After intravenous and intramuscular administration, high concentrations of sulbactam and ampicillin in the blood are achieved.
T1/2 – 1 h (for ampicillin and sulbactam). It is excreted by the kidneys – 70-80%, mainly unchanged, as well as with bile and breast milk.
Sulbactam undergoes almost no metabolic transformations and is excreted by the kidneys, mainly unchanged and only about 25% as metabolites.
Indications
Treatment of infectious and inflammatory diseases caused by susceptible pathogens: respiratory tract infections (including pneumonia, lung abscess, chronic bronchitis, pleural empyema); ENT organ infections (including sinusitis, tonsillitis, otitis media); urinary tract and genital organ infections (pyelonephritis, pyelitis, cystitis, urethritis, prostatitis, endometritis); biliary tract infections (cholecystitis, cholangitis); skin and soft tissue infections (erysipelas, impetigo, secondarily infected dermatoses); gastrointestinal tract infections (dysentery, salmonellosis, salmonella carriage); bone and joint infections; septic endocarditis; meningitis; sepsis; peritonitis; scarlet fever; gonococcal infection.
Prevention of postoperative complications during operations on the abdominal and pelvic organs.
ICD codes
| ICD-10 code | Indication |
| A02 | Other salmonella infections |
| A03 | Shigellosis |
| A09 | Other and unspecified gastroenteritis and colitis of infectious origin |
| A38 | Scarlet fever |
| A40 | Streptococcal sepsis |
| A41 | Other sepsis |
| A46 | Erysipelas |
| A54 | Gonococcal infection |
| G00 | Bacterial meningitis, not elsewhere classified |
| H66 | Suppurative and unspecified otitis media |
| I33 | Acute and subacute endocarditis |
| J01 | Acute sinusitis |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J31.2 | Chronic pharyngitis |
| J32 | Chronic sinusitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| J85 | Abscess of lung and mediastinum |
| J86 | Pyothorax (pleural empyema) |
| K65.0 | Acute peritonitis (including abscess) |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K83.0 | Cholangitis |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| L30.3 | Infectious dermatitis (infectious eczema) |
| M00 | Pyogenic arthritis |
| M86 | Osteomyelitis |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N30 | Cystitis |
| N34 | Urethritis and urethral syndrome |
| N37.0 | Urethritis in diseases classified elsewhere |
| N41 | Inflammatory diseases of prostate |
| N70 | Salpingitis and oophoritis |
| N71 | Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess) |
| N72 | Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis) |
| N73.5 | Unspecified female pelvic peritonitis |
| N74.3 | Gonococcal inflammatory diseases of female pelvic organs |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| Z22.1 | Carrier of other infectious gastrointestinal diseases |
| Z29.2 | Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes) |
| ICD-11 code | Indication |
| 1A02 | Intestinal infections due to Shigella |
| 1A09.Z | Salmonella infection, unspecified |
| 1A40.Z | Infectious gastroenteritis or colitis, unspecified |
| 1A7Z | Gonococcal infection, unspecified |
| 1B50 | Scarlet fever |
| 1B70.0Z | Erysipelas, unspecified |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1C44 | Non-pyogenic bacterial infections of skin |
| 1D01.0Z | Bacterial meningitis, unspecified |
| 1G40 | Sepsis without septic shock |
| AA9Z | Unspecified suppurative otitis media |
| BB4Z | Acute or subacute endocarditis, unspecified |
| CA01 | Acute rhinosinusitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA09.2 | Chronic pharyngitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| CA43.Z | Abscess of lung or mediastinum, unspecified |
| CA44 | Pyothorax |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DC13 | Cholangitis |
| DC50.0 | Primary peritonitis |
| DC50.2 | Peritoneal abscess |
| DC50.Z | Peritonitis, unspecified |
| EA50.3 | Staphylococcal scarlet fever |
| EA88.0Z | Infectious dermatitis, unspecified |
| EB21 | Pyoderma gangrenosum |
| FA1Z | Infectious arthropathies, unspecified |
| FB84.Z | Osteomyelitis or osteitis, unspecified |
| GA01.Z | Inflammatory diseases of uterus, except cervix, unspecified |
| GA05.2 | Unspecified pelvic peritonitis in women |
| GA07.Z | Salpingitis and oophoritis, unspecified |
| GA91.Z | Inflammatory and other diseases of prostate, unspecified |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC02.1 | Nonspecific urethritis |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| QC05.Y | Other specified prophylactic measures |
| QD01.Z | Carriage of intestinal infectious agent, unspecified |
| 1A71 | Gonococcal pelviperitonitis |
| GA05.Z | Inflammatory diseases of female pelvic organs, unspecified |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| XA5WW1 | Cervix uteri |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Powder
Intramuscularly, intravenously (by drip at a rate of 60-80 drops/min, by stream – slowly, over 3-5 minutes).
Intravenous administration is used for 5-7 days, then, if it is necessary to continue treatment, switch to intramuscular use.
The following are the total doses of ampicillin and sulbactam (in a 2:1 ratio).
For mild infections – 1.5-3 g/day in 2 administrations; for moderate infections – 3-6 g/day in 3-4 administrations; for severe infections – 12 g/day in 3-4 administrations.
For uncomplicated gonorrhea – 1.5 g, once.
For prevention of surgical infections – 1.5-3 g, during anesthesia; then within 24 hours after surgery – at the same dose every 6-8 hours.
For children – in a daily dose of 150 mg/kg (100 mg/kg ampicillin and 50 mg/kg sulbactam); frequency – 3-4 times/day.
For newborns under 1 week of age and premature infants – every 12 hours.
The course of treatment is 5-14 days (can be extended if necessary). After normalization of temperature and disappearance of other pathological symptoms, treatment is continued for another 48 hours.
In chronic renal failure (creatinine clearance less than 30 ml/min), it is necessary to increase the intervals between administrations.
Adverse Reactions
From the digestive system: nausea, vomiting, decreased appetite, diarrhea, increased activity of “liver” transaminases; rarely – pseudomembranous enterocolitis.
From the hematopoietic organs and hemostasis system: anemia, leukopenia, thrombocytopenia.
From the nervous system: drowsiness, malaise, headache.
Laboratory parameters: azotemia, increased urea concentration, hypercreatininemia.
Allergic reactions: urticaria, skin hyperemia, angioedema, rhinitis, conjunctivitis, fever, arthralgia, eosinophilia, in rare cases – anaphylactic shock.
Local reactions: with intramuscular administration – pain at the injection site; with intravenous – phlebitis.
Other: with prolonged treatment – superinfection caused by microorganisms resistant to the drug (candidiasis).
Contraindications
Hypersensitivity to the components of the drug; infectious mononucleosis; lactation period (breastfeeding).
With caution
Hepatic and/or renal failure, pregnancy.
Use in Pregnancy and Lactation
Use with caution during pregnancy. Contraindicated for use during lactation (breastfeeding).
Use in Hepatic Impairment
With caution: hepatic insufficiency.
Use in Renal Impairment
With caution: renal insufficiency.
Pediatric Use
Use is possible according to the dosage regimen.
Special Precautions
In patients with hypersensitivity to penicillins, cross-allergic reactions with cephalosporin antibiotics are possible.
During course treatment, it is necessary to monitor the state of the function of the hematopoietic organs, liver and kidneys.
The development of superinfection due to the growth of microflora insensitive to the drug is possible, which requires an appropriate change in antibacterial therapy.
When treating patients with sepsis, the development of a bacteriolysis reaction (Jarisch-Herxheimer reaction) is possible.
Drug Interactions
Antacids, glucosamine, laxatives, food, aminoglycosides (when taken orally) slow down and reduce absorption.
Ascorbic acid increases absorption.
Bactericidal antibiotics (including aminoglycosides, cephalosporins, cycloserine, vancomycin, rifampicin) – synergism of action; bacteriostatic drugs (macrolides, chloramphenicol, lincosamides, tetracyclines, sulfonamides) – antagonism of action.
Increases the effectiveness of indirect anticoagulants (by suppressing intestinal microflora, reduces the synthesis of vitamin K and the prothrombin index); reduces the effectiveness of oral contraceptives, drugs in the metabolism of which PABA is formed, and ethinyl estradiol (risk of “breakthrough” bleeding).
Diuretics, allopurinol, phenylbutazone, NSAIDs and other drugs that reduce tubular secretion increase the concentration of ampicillin in plasma.
Allopurinol increases the risk of skin rash.
Pharmaceutical incompatibility
With blood products or protein hydrolysates, aminoglycosides.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Powder for solution for intravenous and intramuscular injection 500 mg+250 mg: vial 1, 10 pcs or 50 pcs.
Powder for solution for intravenous and intramuscular injection 1000 mg+500 mg: vial 1, 10 pcs or 50 pcs.
Marketing Authorization Holder
AlTro, LLC (Russia)
Manufactured By
Reyoung Pharmaceutical, Co., Ltd. (China)
Dosage Forms
| Ampicillin + Sulbactam | Powder for solution for intravenous and intramuscular injection 500 mg+250 mg: vial 1, 10 pcs or 50 pcs. | |
| Powder for solution for intravenous and intramuscular injection 1000 mg+500 mg: vial 1, 10 pcs or 50 pcs. |
Dosage Form, Packaging, and Composition
Powder for solution for intravenous and intramuscular injection white or almost white with a yellowish tint.
| 1 vial | |
| Ampicillin (as sodium salt) | 500 mg |
| Sulbactam (as sodium salt) | 250 mg |
Vials with a capacity of 10 ml (1) – cardboard packs.
Vials with a capacity of 10 ml (10) – plastic contour packages (trays) (1) – cardboard packs.
Vials with a capacity of 10 ml (50) – plastic contour packages (trays) (1) – cardboard packs.
Powder for solution for intravenous and intramuscular injection white or almost white with a yellowish tint.
| 1 vial | |
| Ampicillin (as sodium salt) | 1000 mg |
| Sulbactam (as sodium salt) | 500 mg |
Vials with a capacity of 20 ml (1) – cardboard packs.
Vials with a capacity of 20 ml (10) – plastic contour packages (trays) (1) – cardboard packs.
Vials with a capacity of 20 ml (50) – plastic contour packages (trays) (1) – cardboard packs.
Powder for solution for intravenous and intramuscular administration 1 g+500 mg: vial. 1 pc.
Powder for solution for intravenous and intramuscular administration 2 g+1 g: fl. 1 pc.
Powder for solution for intravenous and intramuscular administration 250 mg+125 mg: vial 1 pc.
Powder for solution for intravenous and intramuscular administration 500 mg+250 mg: vial. 1 pc.
Marketing Authorization Holder
Jodas Expoim, LLC (Russia)
Manufactured By
Jodas Expoim, Pvt. Ltd. (India)
Or
Interpharma, LLC (Russia)
Dosage Forms
| Ampicillin + Sulbactam | Powder for solution for intravenous and intramuscular administration 1 g+500 mg: vial. 1 pc. | |
| Powder for solution for intravenous and intramuscular administration 2 g+1 g: fl. 1 pc. | ||
| Powder for solution for intravenous and intramuscular administration 250 mg+125 mg: vial 1 pc. | ||
| Powder for solution for intravenous and intramuscular administration 500 mg+250 mg: vial. 1 pc. |
Dosage Form, Packaging, and Composition
Powder for solution for intravenous and intramuscular administration white or white with a yellowish tint.
| 1 vial | |
| Ampicillin sodium | 1062.9 mg, |
| Equivalent to ampicillin content | 1000 mg |
| Sulbactam sodium | 547.2 mg, |
| Equivalent to sulbactam content | 500 mg |
Colorless glass vials (1) – cardboard packs.
Colorless glass vials (1) with solvent (water for injection – Registration Certificate No. LP-002377 dated 18.02.2014; amp. 5 ml or 10 ml 1 pc.) – cardboard packs.
Powder for solution for intravenous and intramuscular administration white or white with a yellowish tint.
| 1 vial | |
| Ampicillin sodium | 2125.8 mg, |
| Equivalent to ampicillin content | 2000 mg |
| Sulbactam sodium | 1094.4 mg, |
| Equivalent to sulbactam content | 1000 mg |
Colorless glass vials (1) – cardboard packs.
Colorless glass vials (1) with solvent (water for injection – Registration Certificate No. LP-002377 dated 18.02.2014; amp. 5 ml or 10 ml 1 pc.) – cardboard packs.
Powder for solution for intravenous and intramuscular administration white or white with a yellowish tint.
| 1 vial | |
| Ampicillin sodium | 265.7 mg, |
| Equivalent to ampicillin content | 250 mg |
| Sulbactam sodium | 136.8 mg, |
| Equivalent to sulbactam content | 125 mg |
Colorless glass vials (1) – cardboard packs.
Colorless glass vials (1) with solvent (water for injection – Registration Certificate No. LP-002377 dated 18.02.2014; amp. 5 ml or 10 ml 1 pc.) – cardboard packs.
Powder for solution for intravenous and intramuscular administration white or white with a yellowish tint.
| 1 vial | |
| Ampicillin sodium | 531.5 mg, |
| Equivalent to ampicillin content | 500 mg |
| Sulbactam sodium | 273.6 mg, |
| Equivalent to sulbactam content | 250 mg |
Colorless glass vials (1) – cardboard packs.
Colorless glass vials (1) with solvent (water for injection – Registration Certificate No. LP-002377 dated 18.02.2014; amp. 5 ml or 10 ml 1 pc.) – cardboard packs.
Powder for solution for intravenous and intramuscular injection 2 g+1 g: vial with or without solvent
Marketing Authorization Holder
Kraspharma, PJSC (Russia)
Dosage Form
| Ampicillin + Sulbactam | Powder for solution for intravenous and intramuscular injection 2 g+1 g: vial with or without solvent |
Dosage Form, Packaging, and Composition
Powder for solution for intravenous and intramuscular administration white or almost white, hygroscopic.
| 1 vial | |
| Ampicillin (as sodium salt) | 2000 mg |
| Sulbactam (as sodium salt) | 1000 mg |
Solvent water for injection in amp.
1 pc. – 5 ml vials (1) – cardboard packs.
1 pc. – 10 ml vials (1) – cardboard packs.
1 pc. – 5 ml vials (1) (1-50 pcs.) – cardboard boxes (for hospitals).
1 pc. – 10 ml vials (1) (1-50 pcs.) – cardboard boxes (for hospitals).
1 pc. – 5 ml vials (1) – cardboard packs (with solvent: 5 ml amp. 2 pcs. and ampoule opener).
1 pc. – 10 ml vials (1) – cardboard packs (with solvent: 10 ml amp. 1 pc. and ampoule opener).
1 pc. – 5 ml vials (5) – cardboard packs (with solvent: 5 ml amp. 10 pcs. and ampoule opener).
1 pc. – 10 ml vials (5) – cardboard packs (with solvent: 10 ml amp. 5 pcs. and ampoule opener).
Powder for solution for intravenous and intramuscular injection 500 mg+250 mg: vial 10 pcs.
Marketing Authorization Holder
Kraspharma, PJSC (Russia)
Dosage Form
| Ampicillin + Sulbactam | Powder for solution for intravenous and intramuscular injection 500 mg+250 mg: vial 10 pcs. |
Dosage Form, Packaging, and Composition
| Powder for solution for intravenous and intramuscular administration | 1 vial |
| Ampicillin (as sodium salt) | 500 mg |
| Sulbactam (as sodium salt) | 250 mg |
Vials (10) – cardboard packs.
Powder for solution for intravenous and intramuscular injection 1 g+500 mg: vial 10 pcs.
Marketing Authorization Holder
Kraspharma, PJSC (Russia)
Dosage Form
| Ampicillin + Sulbactam | Powder for solution for intravenous and intramuscular injection 1 g+500 mg: vial 10 pcs. |
Dosage Form, Packaging, and Composition
| Powder for solution for intravenous and intramuscular administration | 1 vial |
| Ampicillin (as sodium salt) | 1 g |
| Sulbactam (as sodium salt) | 500 mg |
Vials (10) – cardboard packs.
Powder for solution for intravenous and intramuscular injection 500 mg+250 mg: vial 1, 5 or 10 pcs.
Powder for solution for intravenous and intramuscular injection 1000 mg+500 mg: vial 1, 5 or 10 pcs.
Powder for solution for intravenous and intramuscular injection 2000 mg+1000 mg: vial 1, 5 or 10 pcs.
Marketing Authorization Holder
Promomed Rus LLC (Russia)
Manufactured By
Biokhimik, JSC (Russia)
Dosage Forms
| Ampicillin + Sulbactam | Powder for solution for intravenous and intramuscular injection 500 mg+250 mg: vial 1, 5 or 10 pcs. | |
| Powder for solution for intravenous and intramuscular injection 1000 mg+500 mg: vial 1, 5 or 10 pcs. | ||
| Powder for solution for intravenous and intramuscular injection 2000 mg+1000 mg: vial 1, 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Powder for solution for intravenous and intramuscular administration white or almost white, crystalline.
| 1 vial | |
| Ampicillin sodium | 531.5 mg, |
| Equivalent to ampicillin content | 500 mg |
| Sulbactam sodium | 273.6 mg, |
| Equivalent to sulbactam content | 250 mg |
Glass vials (1) – cardboard packs.
Glass vials (5) – cardboard packs.
Glass vials (10) – cardboard packs.
Glass vials (1) with solvent* (amp. 5 ml 1 pc.) – cardboard packs.
Glass vials (5) with solvent* (amp. 5 ml 5 pcs.) – cardboard packs.
Glass vials (10) with solvent* (amp. 5 ml 10 pcs.) – cardboard packs.
Solvent water for injection or 0.5% novocaine solution.
Powder for solution for intravenous and intramuscular administration white or almost white, crystalline.
| 1 vial | |
| Ampicillin sodium | 1062.9 mg, |
| Equivalent to ampicillin content | 1000 mg |
| Sulbactam sodium | 547.2 mg, |
| Equivalent to sulbactam content | 500 mg |
Glass vials (1) – cardboard packs.
Glass vials (5) – cardboard packs.
Glass vials (10) – cardboard packs.
Glass vials (1) with solvent* (amp. 5 ml 1 pc.) – cardboard packs.
Glass vials (5) with solvent* (amp. 5 ml 5 pcs.) – cardboard packs.
Glass vials (10) with solvent* (amp. 5 ml 10 pcs.) – cardboard packs.
Solvent water for injection or 0.5% novocaine solution.
Powder for solution for intravenous and intramuscular administration white or almost white, crystalline.
| 1 vial | |
| Ampicillin sodium | 2125.8 mg, |
| Equivalent to ampicillin content | 2000 mg |
| Sulbactam sodium | 1094.4 mg, |
| Equivalent to sulbactam content | 1000 mg |
Glass vials (1) – cardboard packs.
Glass vials (5) – cardboard packs.
Glass vials (10) – cardboard packs.
Glass vials (1) with solvent* (amp. 5 ml 2 pcs.) – cardboard packs.
Glass vials (5) with solvent* (amp. 5 ml 10 pcs.) – cardboard packs.
Glass vials (10) with solvent* (amp. 5 ml 20 pcs.) – cardboard packs.
Solvent water for injection or 0.5% novocaine solution.
Powder for solution for intravenous and intramuscular administration 250 mg+125 mg: vial 1, 5, 10 or 50 pcs.
Powder for solution for intravenous and intramuscular administration 500 mg+250 mg: vial 1, 5, 10 or 50 pcs.
Powder for solution for intravenous and intramuscular administration 1000 mg+500 mg: vial 1, 5, 10 or 50 pcs.
Powder for solution for intravenous and intramuscular injection 2000 mg+1000 mg
Marketing Authorization Holder
Alvils, LLC (Russia)
Manufactured By
Belarusian-Dutch Joint Venture "FARMLAND", LLC (Republic of Belarus)
Dosage Forms
| Ampicillin + Sulbactam-Alvils | Powder for solution for intravenous and intramuscular administration 250 mg+125 mg: vial 1, 5, 10 or 50 pcs. | |
| Powder for solution for intravenous and intramuscular administration 500 mg+250 mg: vial 1, 5, 10 or 50 pcs. | ||
| Powder for solution for intravenous and intramuscular administration 1000 mg+500 mg: vial 1, 5, 10 or 50 pcs. | ||
| Powder for solution for intravenous and intramuscular injection 2000 mg+1000 mg |
Dosage Form, Packaging, and Composition
Powder for solution for intravenous and intramuscular administration
| 1 vial | |
| Ampicillin (as sodium salt) | 250 mg |
| Sulbactam (as sodium salt) | 125 mg |
375 mg – vials – cardboard packs – Prescription only
375 mg – vials (10 pcs.) – cardboard packs – Prescription only
375 mg – vials (5 pcs.) – cardboard packs – Prescription only
Powder for solution for intravenous and intramuscular administration
| 1 vial | |
| Ampicillin (as sodium salt) | 500 mg |
| Sulbactam (as sodium salt) | 250 mg |
750 mg – vials – cardboard packs – Prescription only
750 mg – vials (10 pcs.) – cardboard packs – Prescription only
750 mg – vials (5 pcs.) – cardboard packs – Prescription only
Powder for solution for intravenous and intramuscular administration
| 1 vial | |
| Ampicillin (as sodium salt) | 1000 mg |
| Sulbactam (as sodium salt) | 500 mg |
1500 mg – vials – cardboard packs – Prescription only
1500 mg – vials (10 pcs.) – cardboard packs – Prescription only
1500 mg – vials (5 pcs.) – cardboard packs – Prescription only
Powder for solution for intravenous and intramuscular administration
| 1 vial | |
| Ampicillin (as sodium salt) | 2000 mg |
| Sulbactam (as sodium salt) | 1000 mg |
3000 mg – vials – cardboard packs – Prescription only
3000 mg – vials (10 pcs.) – cardboard packs – Prescription only
3000 mg – vials (5 pcs.) – cardboard packs – Prescription only
Powder for solution for intravenous and intramuscular administration 250 mg+125 mg: vial 1, 5, 10 or 50 pcs.
Powder for solution for intravenous and intramuscular administration 500 mg+250 mg: vial 1, 5, 10 or 50 pcs.
Powder for solution for intravenous and intramuscular administration 1000 mg+500 mg: vial 1, 5, 10 or 50 pcs.
Powder for solution for intravenous and intramuscular injection 2000 mg+1000 mg
Marketing Authorization Holder
Protek-SVM LLC (Russia)
Manufactured By
Ruzpharma, LLC (Russia)
Dosage Forms
| Ampicillin + Sulbactam-LEKSVM® | Powder for solution for intravenous and intramuscular administration 250 mg+125 mg: vial 1, 5, 10 or 50 pcs. | |
| Powder for solution for intravenous and intramuscular administration 500 mg+250 mg: vial 1, 5, 10 or 50 pcs. | ||
| Powder for solution for intravenous and intramuscular administration 1000 mg+500 mg: vial 1, 5, 10 or 50 pcs. | ||
| Powder for solution for intravenous and intramuscular injection 2000 mg+1000 mg |
Dosage Form, Packaging, and Composition
Powder for solution for intravenous and intramuscular administration
| 1 vial | |
| Ampicillin (as sodium salt) | 250 mg |
| Sulbactam (as sodium salt) | 125 mg |
375 mg – vials – cardboard packs – Prescription only
375 mg – vials (50 pcs.) – cardboard boxes – for hospitals
Powder for solution for intravenous and intramuscular administration
| 1 vial | |
| Ampicillin (as sodium salt) | 500 mg |
| Sulbactam (as sodium salt) | 250 mg |
750 mg – vials – cardboard packs – Prescription only
750 mg – vials (50 pcs.) – cardboard boxes – for hospitals
Powder for solution for intravenous and intramuscular administration
| 1 vial | |
| Ampicillin (as sodium salt) | 1000 mg |
| Sulbactam (as sodium salt) | 500 mg |
1500 mg – vials – cardboard packs – Prescription only
1500 mg – vials (50 pcs.) – cardboard boxes – for hospitals
Powder for solution for intravenous and intramuscular administration
| 1 vial | |
| Ampicillin (as sodium salt) | 2000 mg |
| Sulbactam (as sodium salt) | 1000 mg |
3000 mg – vials – cardboard packs – Prescription only
3000 mg – vials (50 pcs.) – cardboard boxes – for hospitals
Phenibut-Vertex pills 250mg, 20pcs
Arbidol, capsules 100mg, 40pcs
Cortexin, 10mg, 5ml, 10pcs
Nootropil pills 800mg, 30pcs
Picamilon pills 50mg, 60pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Belosalic, ointment, 30g 